Pharmaceutical

FDA priority review advances Atara’s tabelecleucel for viral infection

Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.

Jul 18, 2024 - 04:00
FDA priority review advances Atara’s tabelecleucel for viral infection
Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.
Read the original article

Tags:

Previous Article

Smart soil can water and feed itself

Next Article

Gene therapy: How the CRO of Veristat cut trial database costs by 30%

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Teva and Royalty Pharma to expedite olanzapine LAI research programme

Teva and Royalty Pharma to expedite olanzapine LAI rese...

Nov 14, 2023

Madrigal seeks expedited approval for NASH treatment

Madrigal seeks expedited approval for NASH treatment

Jul 3, 2023

STAT+: Large insurers say up to one-quarter of claims run through Change Healthcare

STAT+: Large insurers say up to one-quarter of claims r...

Mar 6, 2024